Questions over AstraZeneca’s COVID-19 vaccine data risk delaying approval
Days after grabbing headlines with its COVID-19 “vaccine for the world”, AstraZeneca is facing tricky questions about its success rate that some experts say could hinder its chances of getting speedy US and EU regulatory approval.
